Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evalstotug (BA3071) in Solid Tumors
NCT05180799Phase 2Active, not recruiting
- Sponsor
- BioAtla
- Start
- Aug 2022
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of Evalstotug in solid tumor, melanoma, non-small cell lung cancer (NSCLC), sponsored by BioAtla. Started Aug 2022; status: active, not recruiting.
02
Drugs
Evalstotug
03
Conditions
solid tumormelanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05180799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05180799.